SEP
CORT icon

Signature Equity Partners’s Corcept Therapeutics CORT Stock Holding History

Signature Equity Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61K Buy
701
+101
+17% +$6.1K 0.03% 385
2026
Q1 		$24.2K Sell
600
-31
-5% -$1.16K 0.01% 591
2025
Q4 		$22K Buy
+631
New +$49.6K 0.01% 612

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Signature Equity Partners's CORT Position: Q2 2026 in Review

Signature Equity Partners increased its Corcept Therapeutics (CORT) stake by 17% in Q2 2026, buying an estimated $6.1K and bringing the position to 701 shares worth $61K. The position accounts for 0.03% of the portfolio, ranked #385.

Signature Equity Partners first reported a position in CORT in Q4 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Signature Equity Partners held 701 shares of Corcept Therapeutics worth $61K as of Q2 2026.
  • Signature Equity Partners bought 101 Corcept Therapeutics shares in Q2 2026, an estimated $6.1K.
  • Corcept Therapeutics made up 0.03% of Signature Equity Partners's portfolio in Q2 2026, its #385 holding.
  • Signature Equity Partners first reported a position in Corcept Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.